[{"address1": "60 Jubilee Avenue", "address2": "Milton Park", "city": "Abingdon", "zip": "OX14 4RX", "country": "United Kingdom", "phone": "44 12 3543 0000", "fax": "44 12 3543 0001", "website": "https://www.adaptimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.", "fullTimeEmployees": 449, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adrian G.  Rawcliffe", "age": 51, "title": "CEO, Principal Accounting Officer & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1057878, "exercisedValue": 199161, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen Katrina Tayton-Martin MBA, Ph.D.", "age": 56, "title": "Co-Founder & Chief Business & Strategy Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 677404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gavin Hilary James Wood ACA, BA (Hons)", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 666344, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William C. A. Bertrand Jr., Esq., J.D.", "age": 58, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 707338, "exercisedValue": 76949, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elliot  Norry B.A., M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 676194, "exercisedValue": 65024, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joanna  Brewer Ph.D.", "age": 47, "title": "Chief Scientific Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juli P. Miller Ph.D.", "title": "VP of Corporate Affairs & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kerry  Sharp", "title": "Senior VP & General Council", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dana  Lynch", "title": "Senior Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Lunger", "age": 53, "title": "Chief Patient Supply Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 645908, "exercisedValue": 148202, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.16, "open": 1.17, "dayLow": 1.09, "dayHigh": 1.19, "regularMarketPreviousClose": 1.16, "regularMarketOpen": 1.17, "regularMarketDayLow": 1.09, "regularMarketDayHigh": 1.19, "beta": 2.203, "forwardPE": -2.5813954, "volume": 1518981, "regularMarketVolume": 1518981, "averageVolume": 1900751, "averageVolume10days": 1262570, "averageDailyVolume10Day": 1262570, "bid": 1.1, "ask": 1.13, "bidSize": 1000, "askSize": 800, "marketCap": 283876960, "fiftyTwoWeekLow": 0.42, "fiftyTwoWeekHigh": 2.05, "priceToSalesTrailing12Months": 2.006779, "fiftyDayAverage": 1.15518, "twoHundredDayAverage": 1.062095, "currency": "USD", "enterpriseValue": 1612547328, "profitMargins": -0.51252, "floatShares": 1023293789, "sharesOutstanding": 255744992, "sharesShort": 7130362, "sharesShortPriorMonth": 6298988, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0279, "heldPercentInsiders": 0.0037599998, "heldPercentInstitutions": 0.61847, "shortRatio": 2.85, "shortPercentOfFloat": 0.0418, "impliedSharesOutstanding": 226172000, "bookValue": 0.377, "priceToBook": 2.944297, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -72500000, "trailingEps": -0.36, "forwardEps": -0.43, "pegRatio": -2.76, "enterpriseToRevenue": 11.399, "enterpriseToEbitda": -22.126, "52WeekChange": 0.5163399, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ADAP", "underlyingSymbol": "ADAP", "shortName": "Adaptimmune Therapeutics plc", "longName": "Adaptimmune Therapeutics plc", "firstTradeDateEpochUtc": 1430919000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d9a36f50-8d36-3b28-b886-83aa23ac2f63", "messageBoardId": "finmb_113495056", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.11, "targetHighPrice": 4.0, "targetLowPrice": 1.0, "targetMeanPrice": 2.56, "targetMedianPrice": 2.5, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 214788992, "totalCashPerShare": 0.14, "ebitda": -72880000, "totalDebt": 47348000, "quickRatio": 2.907, "currentRatio": 3.092, "totalRevenue": 141459008, "debtToEquity": 49.18, "revenuePerShare": 0.595, "returnOnAssets": -0.15837, "returnOnEquity": -0.65044, "freeCashflow": -7946125, "operatingCashflow": -44386000, "revenueGrowth": 23.996, "grossMargins": -0.0367, "ebitdaMargins": -0.5152, "operatingMargins": 0.53575003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]